136 related articles for article (PubMed ID: 19477412)
1. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists.
Germain P; Gaudon C; Pogenberg V; Sanglier S; Van Dorsselaer A; Royer CA; Lazar MA; Bourguet W; Gronemeyer H
Chem Biol; 2009 May; 16(5):479-89. PubMed ID: 19477412
[TBL] [Abstract][Full Text] [Related]
2. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
3. C3 halogen and c8'' substituents on stilbene arotinoids modulate retinoic Acid receptor subtype function.
Alvarez S; Khanwalkar H; Alvarez R; Erb C; Martínez C; Rodríguez-Barrios F; Germain P; Gronemeyer H; de Lera AR
ChemMedChem; 2009 Oct; 4(10):1630-40. PubMed ID: 19670208
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists.
Géhin M; Vivat V; Wurtz JM; Losson R; Chambon P; Moras D; Gronemeyer H
Chem Biol; 1999 Aug; 6(8):519-29. PubMed ID: 10421757
[TBL] [Abstract][Full Text] [Related]
5. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells.
Hammond LA; Van Krinks CH; Durham J; Tomkins SE; Burnett RD; Jones EL; Chandraratna RA; Brown G
Br J Cancer; 2001 Aug; 85(3):453-62. PubMed ID: 11487280
[TBL] [Abstract][Full Text] [Related]
6. Determinants of retinoid X receptor transcriptional antagonism.
Cavasotto CN; Liu G; James SY; Hobbs PD; Peterson VJ; Bhattacharya AA; Kolluri SK; Zhang XK; Leid M; Abagyan R; Liddington RC; Dawson MI
J Med Chem; 2004 Aug; 47(18):4360-72. PubMed ID: 15317450
[TBL] [Abstract][Full Text] [Related]
7. Inverse agonists and antagonists of retinoid receptors.
Bourguet W; de Lera AR; Gronemeyer H
Methods Enzymol; 2010; 485():161-95. PubMed ID: 21050917
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Retinoic Acid Receptor Subtypes by 5- and 8-Substituted (Naphthalen-2-yl)-based Arotinoids.
Álvarez S; Lieb M; Martínez C; Khanwalkar H; Rodríguez-Barrios F; Álvarez R; Gronemeyer H; de Lera AR
ChemMedChem; 2015 Aug; 10(8):1378-91. PubMed ID: 26012882
[TBL] [Abstract][Full Text] [Related]
9. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
de Lera AR; Bourguet W; Altucci L; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
[TBL] [Abstract][Full Text] [Related]
10. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor.
Alvarez S; Germain P; Alvarez R; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Int J Biochem Cell Biol; 2007; 39(7-8):1406-15. PubMed ID: 17433757
[TBL] [Abstract][Full Text] [Related]
11. An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist.
Nadendla E; Teyssier C; Delfosse V; Vivat V; Krishnasamy G; Gronemeyer H; Bourguet W; Germain P
PLoS One; 2015; 10(5):e0123195. PubMed ID: 25933005
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid receptor modulators: a perspective on recent advances and promises.
Alvarez S; Bourguet W; Gronemeyer H; de Lera AR
Expert Opin Ther Pat; 2011 Jan; 21(1):55-63. PubMed ID: 21091043
[TBL] [Abstract][Full Text] [Related]
13. Corepressor interaction differentiates the permissive and non-permissive retinoid X receptor heterodimers.
Lammi J; Perlmann T; Aarnisalo P
Arch Biochem Biophys; 2008 Apr; 472(2):105-14. PubMed ID: 18282463
[TBL] [Abstract][Full Text] [Related]
14. Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists.
Alvarez S; Alvarez R; Khanwalkar H; Germain P; Lemaire G; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Bioorg Med Chem; 2009 Jul; 17(13):4345-59. PubMed ID: 19482478
[TBL] [Abstract][Full Text] [Related]
15. RAR and RXR modulation in cancer and metabolic disease.
Altucci L; Leibowitz MD; Ogilvie KM; de Lera AR; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):793-810. PubMed ID: 17906642
[TBL] [Abstract][Full Text] [Related]
16. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
[TBL] [Abstract][Full Text] [Related]
17. Rational design of RAR-selective ligands revealed by RARbeta crystal stucture.
Germain P; Kammerer S; Pérez E; Peluso-Iltis C; Tortolani D; Zusi FC; Starrett J; Lapointe P; Daris JP; Marinier A; de Lera AR; Rochel N; Gronemeyer H
EMBO Rep; 2004 Sep; 5(9):877-82. PubMed ID: 15319780
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Lund BW; Piu F; Gauthier NK; Eeg A; Currier E; Sherbukhin V; Brann MR; Hacksell U; Olsson R
J Med Chem; 2005 Dec; 48(24):7517-9. PubMed ID: 16302793
[TBL] [Abstract][Full Text] [Related]
19. Imaging of selective nuclear receptor modulator-induced conformational changes in the nuclear receptor to allow interaction with coactivator and corepressor proteins in living cells.
Awais M; Sato M; Umezawa Y
Chembiochem; 2007 May; 8(7):737-43. PubMed ID: 17387660
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of the stem cell response to retinoic acid and synthetic retinoid analogues: identification of major retinoid-inducible proteins.
Maltman DJ; Christie VB; Collings JC; Barnard JH; Fenyk S; Marder TB; Whiting A; Przyborski SA
Mol Biosyst; 2009 May; 5(5):458-71. PubMed ID: 19381361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
